Ocular surface disease (OSD) is complex and multifactorial, with contributors like meibomian gland dysfunction (MGD), Demodex blepharitis (DB), inflammation, and corneal nerve compromise. This supplement distills key insights from leading faculty, offering concise, actionable strategies for eye care practitioners.

Why It’s Essential:

This supplement provides a concise, actionable reference for busy clinicians, helping them integrate evidence-based diagnostics, therapies, and communication strategies into daily practice.

Faculty Insights Include:

• Marc R. Bloomenstein, OD, FAAO – Schwartz Laser Eye Center, Scottsdale, AZ

• Douglas K. DeVries, OD – Eye Care Associates of Nevada, Sparks, NV

• Lindsay Bull, OD, FAAO – EyeCare Associates of South Tulsa, OK

• Mitch Ibach, OD, FAAO – Vance Thompson Vision, Sioux Falls, SD

• Cory J. Lappin, OD, MS, FAAO – The Dry Eye Center of Ohio, Montgomery

What You’ll Learn:

• Root Causes & Risk Factors: Identify MGD, DB, and inflammatory drivers early to improve patient outcomes.

• Practical Diagnostics: Tips on slit-lamp exams, corneal sensitivity testing, meibography, tear osmolarity, and biomarkers (MMP-9).

• Targeted Treatments: Evidence-based approaches including mechanical expression, IPL, Demodex eradication, and pharmacologic therapies such as cyclosporine (0.05%, 0.09%, 0.1%) and lifitegrast 5%.

• Patient Communication: How to set expectations, educate patients, and improve adherence.

Accreditation Statement

Sponsored by:

The Fundingsland Group, LLC is a COPE-Approved Administrator.

This activity, COPE Activity Number 131949, is accredited by COPE for continuing education for optometrists. This course is approved for .50 hours of CE.
Course # 101677-TD
Activity # 131949

COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.

Supported by unrestricted educational grants from Dompé US, Harrow, Johnson & Johnson Vision, Sun Pharmaceutical Industries, and Thea Pharma.